Marc Tessier Lavigne Denali Therapeutics Inc. (DNLI) insider trading activity

Marc Tessier Lavigne is Director of Denali Therapeutics Inc.. Currently has a direct ownership of 1.88 Million shares of DNLI, which is worth approximately $46.4 Million. The most recent transaction as insider was on May 31, 2024, when has been sold 5,967 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 1.88M

0% 3M change

0.32% 12M change

Total Value Held $46.4 Million

Marc Tessier-Lavigne Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
May 31 2024	BUY Grant, award, or other acquisition	-	5,967 Added 0.32%	1,880,539 Common Stock
Jun 01 2023	BUY Grant, award, or other acquisition	-	4,216 Added 0.22%	1,874,572 Common Stock
Nov 23 2022	SELL Open market or private sale	$609,600 $30.48 p/Share	20,000 Reduced 1.06%	1,870,356 Common Stock
Nov 02 2022	SELL Open market or private sale	$341,273 $30.33 p/Share	11,252 Reduced 0.59%	1,890,356 Common Stock
Nov 01 2022	SELL Open market or private sale	$264,189 $30.2 p/Share	8,748 Reduced 0.46%	1,901,608 Common Stock
Sep 28 2022	SELL Open market or private sale	$618,200 $30.91 p/Share	20,000 Reduced 1.04%	1,910,356 Common Stock
Aug 23 2022	SELL Open market or private sale	$640,400 $32.02 p/Share	20,000 Reduced 1.03%	1,930,356 Common Stock
Jul 25 2022	SELL Open market or private sale	$717,600 $35.88 p/Share	20,000 Reduced 1.02%	1,950,356 Common Stock
Jun 24 2022	SELL Sale (or disposition) back to the issuer	$1,440,367 $30.81 p/Share	46,750 Reduced 2.32%	1,970,356 Common Stock
Jun 23 2022	SELL Sale (or disposition) back to the issuer	$412,075 $31.1 p/Share	13,250 Reduced 0.65%	2,017,106 Common Stock
Jun 02 2022	BUY Grant, award, or other acquisition	-	5,986 Added 0.29%	2,030,356 Common Stock
Mar 23 2022	SELL Open market or private sale	$675,400 $33.77 p/Share	20,000 Reduced 0.98%	2,024,370 Common Stock
Oct 04 2021	SELL Bona fide gift	-	300,000 Reduced 11.79%	2,244,370 Common Stock
Jun 07 2021	SELL Open market or private sale	$6,672,524 $70.7 p/Share	94,378 Reduced 3.58%	2,544,370 Common Stock
Jun 07 2021	BUY Exercise of conversion of derivative security	$1,775,250 $18.81 p/Share	94,378 Added 3.45%	2,638,748 Common Stock
Jun 02 2021	BUY Grant, award, or other acquisition	-	2,074 Added 0.08%	2,544,370 Common Stock
May 24 2021	SELL Open market or private sale	$528,536 $60.02 p/Share	8,806 Reduced 0.35%	2,542,296 Common Stock
May 21 2021	SELL Open market or private sale	$2,282,354 $60.13 p/Share	37,957 Reduced 1.47%	2,551,102 Common Stock
May 03 2021	SELL Open market or private sale	$196,292 $60.64 p/Share	3,237 Reduced 0.12%	2,589,059 Common Stock
Apr 01 2021	SELL Open market or private sale	$2,835,000 $56.7 p/Share	50,000 Reduced 1.89%	2,592,296 Common Stock
Mar 01 2021	SELL Open market or private sale	$6,765,000 $67.65 p/Share	100,000 Reduced 3.65%	2,642,296 Common Stock

Also insider at

REGN

REGENERON PHARMACEUTICALS, INC. Healthcare

Director